高级检索
当前位置: 首页 > 详情页

Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Oncology, Beijing Biohealthcare Biotechnology Co. Ltd [2]Department of Oncology, Beijing Tongren Hospital, Capital Medical University [3]Department of Interventional Therapy Center, Beijing Shunyi District Hospital, Beijing, China
出处:
ISSN:

关键词: T-cell exhaustion PD-1 Tim-3 cytotoxic lymphocytes colorectal cancer

摘要:
The paradoxical coexistence of spontaneous tumor antigen-specific immune response with progressive disease in cancer patients need to dissect the molecular pathways involved in tumor induced T-cell dysfunction or exhaustion. Programmed cell death 1 (PD-1) has been identified as a marker of exhausted T cells in chronic disease states, and blockade of PD-1-PD-L1 interactions has been shown to partially restore T-cell function. We have found that T-cell immunoglobulin mucin (Tim) 3 is expressed on CD8(+) tumor-infiltrating lymphocytes (TILs) isolated from patients with colorectal cancer. All T-cell immunoglobulin mucin 3 (Tim-3(+)) TILs coexpress PD-1, and Tim-3(+) PD-1(+) CD8(+) TILs represent the predominant fraction of Tcells infiltrating tumors. Tim-3(+) PD-1(+) CD8(+) TILs exhibit the most severe exhausted phenotype as defined by failure to produce cytokines, such as interferon-gamma, tumor necrosis factor-alpha, and interleukin-2. We further find that combined targeting of the Tim-3 and PD-1 pathways increased the frequencies of not only interferon-gamma and tumor necrosis factor-alpha but also frequencies of proliferating tumor antigen-specific CD8(+) T cells than targeting either pathway alone. A concomitant decrease in regulatory T cells and enhanced killing in a cytotoxicity assay was observed. Collectively, our findings support the use of Tim-3-Tim-3L blockade together with PD-1-PD-L1 blockade to reverse tumor-induced T-cell exhaustion/dysfunction in patients with colorectal cancer.

基金:

基金编号: Z14010101101

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 2 区 医学
小类 | 3 区 免疫学 3 区 医学:研究与实验 3 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 免疫学 4 区 医学:研究与实验 4 区 肿瘤学
JCR分区:
出版当年[2014]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q2 IMMUNOLOGY Q2 ONCOLOGY
最新[2023]版:
Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY Q3 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者机构: [1]Department of Oncology, Beijing Biohealthcare Biotechnology Co. Ltd
通讯作者:
通讯机构: [1]Department of Oncology, Beijing Biohealthcare Biotechnology Co. Ltd [*1]Center for Cancer Research, FL2, Building 3, Park B, Shunyi District Airport High Tech Zoon, Beijing 101300, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:25471 今日访问量:0 总访问量:1498 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)